Immune Research Market

Mifamurtide

A liposomal synthetic analog of the bacterial cell-wall fragment muramyl dipeptide that activates monocytes and macrophages through NOD2, authorized in the European Union since 2009 as Mepact for non-metastatic osteosarcoma but never approved in the United States.

ImmunomodulatorOsteosarcomaMacrophage ActivationNOD2Not FDA Approved

Also referenced as: L-MTP-PE, MTP-PE, CGP 19835A, Junovan, Mepact, mifamurtide sodium

Also appears in: Other

Public product evidence No certificate records are bound to a tracked Mifamurtide product page A record counts here only when a vendor publishes a certificate against one of its own tracked Mifamurtide product pages. Other certificates naming this compound may still exist — search the wider certificate database.
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Immune / inflammation research

Primary research area: Immune. Also surfaces under Other for browsing and discovery.

Body systems
Immune · Muscle & bone

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
6

L-MTP-PE, MTP-PE, CGP 19835A, Junovan, Mepact, mifamurtide sodium

Signal depth
Medium

No FDA label signal · 11 trials · 140 PubMed results

Promising

Mifamurtide has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Mifamurtide has 6 name-matched clinical trials (1 international) (highest phase: Phase 2) and 140 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results.

🌍 1 international trial
Human data
Phase 2
Trial quality
Randomized
Outcomes
Clinical outcomes
Replication
Multiple trials
Literature
Top-tier journals

Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →


What is Mifamurtide?

Mifamurtide is a fully synthetic analog of muramyl dipeptide, the minimal immunostimulatory fragment of the peptidoglycan cell wall common to all bacteria. It is not a conventional peptide. The molecule, muramyl tripeptide phosphatidylethanolamine (MTP-PE), is a glycopeptide-lipid conjugate: an N-acetylmuramic acid sugar carries the tripeptide L-alanine, D-isoglutamine, L-alanine, which is coupled through its C-terminus to the amino group of dipalmitoyl phosphatidylethanolamine, a two-chain phospholipid. The lipid tail anchors the molecule in multilamellar liposomes, and the drug product is always the liposomal form, L-MTP-PE, designed to reach macrophages by intravenous infusion.

Mifamurtide was developed under the code CGP 19835A, studied at MD Anderson Cancer Center and in a US cooperative-group trial, and taken forward by IDM Pharma as Junovan. The European Commission authorized it as Mepact on March 6, 2009 for high-grade resectable non-metastatic osteosarcoma after complete surgical resection, with postoperative multi-agent chemotherapy, in children, adolescents and young adults; the authorization is now held by Esteve Pharmaceuticals S.A. The FDA declined to approve the same dataset in 2007. Mifamurtide is not a research-market peptide in the usual sense: it exists only as a hospital-administered liposomal infusion.

How it works

  • A NOD2 ligand that activates monocytes and macrophages. Muramyl dipeptide is the minimal peptidoglycan motif detected by the intracellular pattern-recognition receptor NOD2, which activates NF-kappaB signaling; the Crohn’s disease-associated 3020insC frameshift fully abrogates that detection (Girardin et al., Journal of Biological Chemistry, 2003;278(11):8869–8872). The European label states that MTP-PE is a specific NOD2 ligand and that macrophage activation by mifamurtide is accompanied by production of TNF-alpha, IL-1beta, IL-6, IL-8 and IL-12 and of the adhesion molecules LFA-1 and ICAM-1, with in vitro-treated human monocytes killing tumor cells but not normal cells.
  • Liposomal delivery targets the phagocytic compartment. MTP-PE is a lipophilic glycopeptide that, intercalated in multilamellar liposomes and injected intravenously, targets lung, liver and spleen macrophages rather than acting on tumor cells directly; the rationale is to control minimal residual disease through pathways distinct from those of cytotoxic drugs (Nardin et al., Current Cancer Drug Targets, 2006;6(2):123–133). In the phase 1 trial, technetium-99m-labeled liposomes localized to liver, spleen, lung, nasopharynx, thyroid and, in two patients, tumor (Murray et al., Journal of Clinical Oncology, 1989;7(12):1915–1925).
  • Monocytes from treated patients become tumoricidal at doses well below the maximum tolerated dose. In 28 phase 1 patients, monocyte-mediated tumor lysis was activated in 24; the maximum tolerated dose was 4 to 6 mg/m2, but the optimal biological dose for macrophage activation was 0.5 to 2.0 mg/m2, since the agent has no direct antiproliferative effect on tumor cells (Kleinerman et al., Cancer Research, 1989;49(16):4665–4670).
  • A reproducible cytokine cascade. In 16 patients with relapsed osteosarcoma rendered disease-free by surgery, infusion produced rapid rises in circulating TNF-alpha (peaking at 1 to 2 hours in 10 of 16 patients) and IL-6 (2 to 3 hours in all patients) after the first dose only, while neopterin and C-reactive protein rose at 24 hours and remained inducible throughout the course (Kleinerman et al., Journal of Clinical Oncology, 1992;10(8):1310–1316). In 21 healthy adults given a single 4 mg infusion, the terminal half-life was 2.05 ± 0.40 hours and heart rate rose without apparent QTc prolongation (Venkatakrishnan et al., European Journal of Clinical Pharmacology, 2012;68(10):1347–1355).

Research status

Early-phase work. The phase 1 trial at MD Anderson escalated liposomal MTP-PE from 0.05 to 12 mg/m2 in 28 evaluable patients with refractory metastatic cancer; toxicity was grade 2 or less in 24 patients and dominated by chills, fever, malaise and nausea, the maximum tolerated dose was 6 mg/m2, and no objective tumor regression was seen (Murray et al., Journal of Clinical Oncology, 1989;7(12):1915–1925). A phase 2 study then treated patients with relapsed osteosarcoma after resection of pulmonary metastases (Kleinerman et al., Journal of Clinical Oncology, 1992;10(8):1310–1316).

INT-0133, the pivotal trial. The Intergroup study, run by the groups that became the Children’s Oncology Group, randomized newly diagnosed patients with osteosarcoma and no clinically detectable metastases in a 2 × 2 factorial design to cisplatin, doxorubicin and high-dose methotrexate with or without ifosfamide and with or without liposomal muramyl tripeptide. The first report, on 677 patients, found 3-year event-free survival of 71% on standard chemotherapy, 68% with MTP added, 61% with ifosfamide added and 78% with both; an interaction between the two additions prevented a factorial analysis, and the authors concluded only that MTP “might” improve event-free survival (Meyers et al., Journal of Clinical Oncology, 2005;23(9):2004–2011). With longer follow-up of 662 patients the interaction was no longer evident, event-free survival trended in favor of MTP (P = .08), and 6-year overall survival improved from 70% to 78% (P = .03; hazard ratio 0.71, 95% CI 0.52–0.96) (Meyers et al., Journal of Clinical Oncology, 2008;26(4):633–638). The European label reports the same dataset as a 28% relative reduction in the risk of death (hazard ratio 0.72, 95% CI 0.53–0.97) in 678 patients aged 1.4 to 30.6 years. A published letter, “Complexities in interpretation of osteosarcoma clinical trial results,” questioned how the findings should be read, with an author reply in the same issue (Hunsberger et al., Journal of Clinical Oncology, 2008;26(18):3103–3104).

Metastatic cohort. Among INT-0133 patients with metastases at diagnosis, 5-year event-free survival was 42% with liposomal MTP-PE (n = 46) versus 26% without (n = 45) (relative risk 0.72; P = .23) and 5-year overall survival 53% versus 40% (P = .27); neither difference reached significance, although the pattern matched the nonmetastatic result (Chou et al., Cancer, 2009;115(22):5339–5348).

The FDA refusal. IDM Pharma filed a new drug application for L-MTP-PE, then called Junovan, in October 2006. In May 2007 the Oncologic Drugs Advisory Committee voted 12 to 2 that the data did not provide substantial evidence of effectiveness. The FDA then issued a not approvable letter, announced by the company on August 28, 2007, requesting data from additional clinical trials; the company said it would amend the application with additional survival data. No US approval followed. The European Commission granted the Mepact marketing authorization on March 6, 2009, following an orphan designation of June 21, 2004; the product left the orphan register in March 2019 at the end of its 10-year market exclusivity. The National Institute for Health and Care Excellence recommended mifamurtide for osteosarcoma in people aged 2 to 30 years in technology appraisal 235, published October 26, 2011.

US patient-access study (NCT00631631). With no approval, Millennium Pharmaceuticals, a Takeda company, sponsored a non-randomized access protocol for high-risk, recurrent or metastatic osteosarcoma from January 2008 to October 2012. Among 205 patients (median age 16.0 years; 71% with active disease), 7,482 infusions produced 3,679 infusion-related adverse events, very rarely grade 3 or 4, and 1- and 2-year overall survival were 71.7% and 45.9% (Anderson et al., Pediatric Blood & Cancer, 2014;61(2):238–244). In adult volunteers, neither mild or moderate hepatic impairment nor mild or moderate renal impairment changed exposure enough to require dose adjustment (Venkatakrishnan et al., British Journal of Clinical Pharmacology, 2014;77(6):998–1010 and 986–997). An expanded-access protocol at Memorial Sloan Kettering Cancer Center (NCT04571229) remains listed as available, last updated May 11, 2026.

European trials after approval. The Italian Sarcoma Group’s ISG/OS-2 (NCT01459484, 225 patients) and the Spanish GEIS-33 study (NCT04383288, 115 patients) used ABCB1/P-glycoprotein overexpression on the diagnostic biopsy to decide who received mifamurtide after surgery. In the merged analysis of 398 patients aged 4 to 40, 204 (51.3%) received mifamurtide; 5-year event-free survival was 71.4% with mifamurtide and chemotherapy versus 58.3% with chemotherapy alone (P = .0139), a difference not confirmed in multivariable analysis (P = .0593) (Palmerini et al., Journal of Clinical Oncology, 2025;43(28):3113–3122). The University of Oxford’s EuroSarc MEMOS trial in metastatic or recurrent disease (NCT02441309) was terminated for poor recruitment after enrolling 8 patients (Barnes et al., BMC Cancer, 2022;22(1):629).

Ongoing trials. UNICANCER’s randomized phase 2 trial of mifamurtide with postoperative chemotherapy in high-risk osteosarcoma (NCT03643133), run at French sites, enrolled 60 patients from October 23, 2018 and is active but no longer recruiting, with a registry-listed primary completion of September 2026 and no results posted. A single-center Polish phase 2 trial of mifamurtide versus sorafenib (DRAGONFLY, NCT07787429, 40 participants planned) opened on April 1, 2026 in Warsaw. Both are academic European studies; neither is directed at a US application.

Market changes. Esteve stopped marketing Mepact in Brazil in 2026, a decision the local registration holder described to ANVISA as commercial and unrelated to quality, efficacy or safety.

Common dosage forms

  • Mepact 4 mg powder for concentrate for dispersion for infusion. The only marketed presentation: a single-use vial containing 4 mg of mifamurtide as a white to off-white lyophilized liposomal powder for intravenous infusion in a specialist oncology unit.
  • Investigational liposomal MTP-PE. The same liposomal preparation, known as CGP 19835A, Junovan or L-MTP-PE, is available in the United States only through an expanded-access protocol.
  • No other presentation. No oral, subcutaneous, intramuscular or non-liposomal form exists.

Key considerations

  • Regulatory status. The Research Market status reflects the absence of any FDA-approved mifamurtide product and of any active US-directed development program as of November 2026. The same INT-0133 data that drew an FDA not approvable letter in August 2007 supported the European Union authorization of Mepact on March 6, 2009, which remains in force under Esteve Pharmaceuticals.
  • One trial, two readings. The approval case rests on a single cooperative-group trial whose prespecified event-free survival endpoint was not met and whose overall survival benefit emerged in a later analysis; European assessors accepted that result and the FDA advisory committee did not.
  • Not a peptide in the usual sense, and not a direct cytotoxic. Mifamurtide is a sugar-tripeptide-phospholipid conjugate that acts only by activating host macrophages through NOD2; it produced no objective responses as a single agent in advanced cancer, and its evidence is confined to the adjuvant setting in osteosarcoma after complete resection, combined with chemotherapy.
  • Infusion reactions are the norm, and ototoxicity is an open question. Chills, fever, headache, fatigue, nausea and tachycardia follow most infusions and track the cytokine release that defines the mechanism. The European label reports more objective hearing loss with mifamurtide plus cisplatin-containing chemotherapy (12%) than with chemotherapy alone (7%) and states that it is unclear whether mifamurtide given with multi-agent chemotherapy increases hearing loss.
  • Mechanism-based interaction logic. Because the drug acts only through macrophage activation, agents that suppress that response, including high-dose NSAIDs and calcineurin inhibitors such as cyclosporine, are expected to blunt its effect, a pharmacodynamic antagonism rather than a metabolic interaction.